Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
-
121
-
122
-
123
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: -
124
-
125
-
126
Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.
Published 2025Subjects: -
127
Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.
Published 2025Subjects: -
128
Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.
Published 2025Subjects: -
129
-
130
-
131
-
132
-
133
-
134
Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.
Published 2025Subjects: -
135
-
136
-
137
-
138
-
139
Klf5 expression is down-regulated in the ruptured human and experimental AAA.
Published 2020Subjects: -
140